Stock TN8 THERMO FISHER SCIENTIFIC
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Thermo Fisher Scientific Deutsche Boerse AG

Equities

TN8

US8835561023

Real-time Estimate Tradegate
Other stock markets
 07:05:56 29/05/2024 BST 		5-day change 1st Jan Change
525.8 EUR +0.07% Intraday chart for Thermo Fisher Scientific -2.69% +9.30%
05-24 Declaration of Voting Results by Thermo Fisher Scientific Inc CI
05-15 Thermo Fisher Scientific Introduces Array-Based Solution for Extended Blood Type Research to Support Future Advancements Toward Safer Transfusions CI

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The company returns high margins, thereby supporting business profitability.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The company is in debt and has limited leeway for investment
  • With an expected P/E ratio at 35.95 and 30.84 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company appears highly valued given the size of its balance sheet.
  • The company is highly valued given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

1st Jan change Capi. Investor Rating ESG Refinitiv
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+9.30% 219B -
DANAHER CORPORATION Stock Danaher Corporation
+11.83% 192B
B-
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+18.87% 142B
B-
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+30.03% 111B
A-
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
+2.32% 65.32B
A-
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+14.15% 52.45B
B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
+2.68% 49.8B
B+
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
+6.60% 43.43B
A
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+1.85% 35.95B -
RESMED, INC. Stock ResMed, Inc.
+20.43% 30.43B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. TMO Stock
  4. TN8 Stock
  5. Ratings Thermo Fisher Scientific